The Proteus Syndrome market is entering a pivotal decade, driven by increasing disease recognition, improving diagnostic techniques, development of genetic testing techniques and other innovative ...

Shares of Regeneron Pharmaceuticals, Inc. REGN have lost 22.6% year to date against the industry’s growth of 0.6%. The stock ...

Regeneron Pharmaceuticals has recently launched a Phase 2 trial, testing the waters with a potential breakthrough in melanoma ...

The survey shows the evolving landscape of nAMD and DME treatments, highlighting physician preferences, payer influences, and ...

Power your summer with an EV! Discover MINI's competitive July lease offer on the 2025 Countryman EV, blending iconic style, all-electric performance, and attractive monthly payments.

The Paroxysmal Nocturnal Hemoglobinuria treatment market is experiencing significant expansion, driven by increasing disease awareness, rising preval ...

Interleukin-2 (IL-2) inhibitors are immunosuppressive agents that block the activity of IL-2, a cytokine involved in the activation and proliferation ...

Recently released research from Spherix Global Insights provides a timely look at the increasingly competitive and complex treatment landscape for neovascular age-related ...

DALLAS, TX , July 10, 2025 (GLOBE NEWSWIRE) -- PatentVest, the first fully integrated IP strategy and legal firm, today announced the release of The Next Era of Surgical Robotics, ...

Analysts’ warnings are a gentle nudge that even giants need to keep proving themselves in a competitive, fast-moving biotech landscape. Staying nimble and delivering innovation will be critical if ...

Sale trumps Regeneron bid The sale to TTAM replaces a $256 million bid for 23andMe by drug maker Regeneron made in May. "We are pleased that the competitive bidding process has resulted in ...